10 completed, 3 recruiting, 3 unknown, 1 not yet recruiting. 18 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 10, Recruiting 3, Unknown 3, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Recruiting 1 |
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout Combined metabolic activators, Collagen and maltodextrin - Gout Disease | Phase 3 | Not yet recruiting | ScandiBio Therapeutics AB | 336 | 2026-10-01 | 2026-10-27 |
| A Study of Dotinurad Versus Allopurinol in Tophaceous Gout Allopurinol, Dotinurad - Tophaceous Gout | Phase 3 | Recruiting | Crystalys Therapeutics | 250 | 2025-08-04 | 2026-09-28 |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout Allopurinol, Dotinurad - Gout | Phase 3 | Recruiting | Crystalys Therapeutics | 500 | 2025-08-01 | 2026-09-28 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 866 | 2025-03-11 | 2026-09-28 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 818 | 2024-06-26 | 2026-10-14 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia | Phase 3 | Completed | LG Chem | 2202 | 2023-03-30 | 2025-07-22 |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Dapansutrile, Placebo Tablet - Acute Gout Flare, Gout Attack | Phase 2 / Phase 3 | Recruiting | Olatec Therapeutics, Inc. | 300 | 2023-01-06 | 2026-03-11 |
| Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Tigulixostat, Placebo - Gout, Hyperuricemia | Phase 3 | Completed | LG Chem | 354 | 2022-10-25 | 2025-10-29 |
| Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms Allopurinol Pill - Musculoskeletal Degeneration, Inflammation | Phase 3 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 200 | 2019-08-30 | 2020-01-23 |
| Long-term Prednisone Use for End-stage Heart Failure prednisone - Heart Failure, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Hebei Medical University | 90 | 2013-12-01 | 2017-01-12 |
| Prednisone for Heart Failure Patients With Hyperuricemia Prednisone, Allopurinol - Heart Failure, Hyperuricemia | Phase 2 / Phase 3 | Completed | Hebei Medical University | 205 | 2013-12-01 | 2018-10-16 |
| Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Febuxostat, Allopurinol - Cardiovascular Disease | Phase 3 | Completed | Takeda | 6198 | 2010-04-23 | 2018-06-14 |
| Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia TULY - Hyperuricemia | Phase 3 | Completed | Virchow Group | 100 | 2010-02-01 | 2014-12-12 |
| Rasburicase (Fasturtec) Registration Trial Rasburicase, Allopurinol - Hyperuricemia | Phase 3 | Terminated | Sanofi | 10 | 2007-10-01 | 2014-05-08 |
| Efficacy and Safety of Oral Febuxostat in Participants With Gout Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Takeda | 2269 | 2007-02-01 | 2012-02-02 |
| Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Rasburicase (SR29142), Allopurinol - Tumor Lysis Syndrome, Cancer | Phase 3 | Completed | Sanofi | 280 | 2004-04-01 | 2010-01-12 |
| Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Febuxostat, Allopurinol - Gout | Phase 3 | Completed | Takeda | 1086 | 2003-07-01 | 2010-07-27 |
Gout (9) · Arthritis, Gouty (3) · Heart Failure (2) · Inflammation (2) · Arthralgia (1) · Arthritis (1) · Cardiovascular Diseases (1) · Leukemia (1) · Lymphoma (1) · Myelodysplastic Syndromes (1) · Myocardial Infarction (1) · Neoplasms (1) · Stroke (1) · Tumor Lysis Syndrome (1)
Pathologic Processes (18) · Pathological Conditions, Signs and Symptoms (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Crystal Arthropathies (9) · Genetic Diseases, Inborn (9) · Joint Diseases (9) · Metabolic Diseases (9) · Metabolism, Inborn Errors (9) · Musculoskeletal Diseases (9) · Nutritional and Metabolic Diseases (9) · Purine-Pyrimidine Metabolism, Inborn Errors (9) · Rheumatic Diseases (9) · Arthritis (8) · Heart Diseases (3) · Cardiovascular Diseases (2)
Allopurinol (10) · Febuxostat (4) · Prednisone (2) · dotinurad (2) · rasburicase (2) · Collagen (1) · Urate Oxidase (1) · dapansutrile (1) · maltodextrin (1)
Takeda (3) · Arthrosi Therapeutics (2) · Crystalys Therapeutics (2) · Hebei Medical University (2) · LG Chem (2) · Sanofi (2) · Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Olatec Therapeutics, Inc. (1) · ScandiBio Therapeutics AB (1) · Virchow Group (1)
United States (10) · China (4) · Spain (3) · Australia (2) · France (2) · Georgia (2) · Mexico (2) · New Zealand (2) · Philippines (2) · Poland (2) · Taiwan (2) · Thailand (2) · Argentina (1) · Belgium (1) · Brazil (1)
Hyungjin Cho, MD (2) · Robert Keenan, MD (2) · Dr. Raghunadharao D (1) · Jing Fu (1) · Luis M Amezcua-Guerra, MD (1)
PMID 39929260, PMID 19286847, PMID 20370912, PMID 21353107, PMID 21849262, PMID 22052584, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22795277, PMID 23683134, PMID 29527974, PMID 35536764, PMID 37072512